Trial Profile
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions; Expanded access; Registrational
- Acronyms RANGER
- Sponsors Biogen
- 03 Dec 2020 Status changed from suspended to discontinued.
- 01 Dec 2020 This trial is Discontinued in UK (Global End Date: 30 Sep 2020), according to European Clinical Trials Database record.
- 18 Oct 2020 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.